• Mashup Score: 3
    FDA Approval of ELFABRIO - 12 month(s) ago

    – PEGylated enzyme replacement therapy designed to provide long half-life*. BOSTON and CARMIEL, Israel, May 10, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development and…

    Source: chiesirarediseases.com
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of MasriAhmadMD
      MasriAhmadMD

      Elfabrio (great name!) is now approved by @US_FDA See a refresher below on Fabry and new treatments. Still awaiting the label to be published Congratulations to the #Fabry & #raredisease community for getting another option for ERT #CardioTwitter https://t.co/MvF21ne5X9 https://t.co/DEGiBtGaVQ